Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187604 | Methods of treating with anti-factor D antibodies The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases a... | 05/29/2012 |
| 8187603 | Antibodies to human IL-22 The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those med... | 05/29/2012 |
| 8182817 | Antibodies to human IL-22 The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those med... | 05/22/2012 |
| 8178100 | Antibodies to IP-10 for treating bone diseases with bone destruction The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specif... | 05/15/2012 |
| 8178101 | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the s... | 05/15/2012 |
| 8178099 | Methods of altering bone growth by administration of sost or wise antagonist or agonist The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one o... | 05/15/2012 |
| 8158127 | Compounds for neutralizing the effects of secreted PLA2 IIA A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfa... | 04/17/2012 |
| 8153130 | Graft-versus-host disease predicting marker and use thereof A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preven... | 04/10/2012 |
| 8153131 | High affinity antibodies against HMGB1 and methods of use thereof Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifical... | 04/10/2012 |
| 8133489 | Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to... | 03/13/2012 |
| 8124090 | Anti-factor D antibodies and methods of treatment The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including ... | 02/28/2012 |
| 8124089 | Anti-human IL-21 monoclonal antibodies Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 ... | 02/28/2012 |
| 8119137 | Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor... | 02/21/2012 |
| 8110191 | Anti-IL-17 antibodies Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragm... | 02/07/2012 |
| 8105597 | Aβ binding molecules The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prev... | 01/31/2012 |
| 8105598 | Human monoclonal antibodies that specifically bind IGF-II Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation const... | 01/31/2012 |
| 8101183 | Variable region sequences of IL-31 monoclonal antibodies The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphig... | 01/24/2012 |
| 8071099 | Anti-FLT3 antibodies The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either ... | 12/06/2011 |
| 8071098 | Method of preventing cerebral vasospasm with anti-HMGB1 antibody An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in contai... | 12/06/2011 |
| 8067003 | Methods of treating conditions using anti-IL-6 antibodies Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus... | 11/29/2011 |
| 8067002 | Humanized anti-factor D antibodies The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases a... | 11/29/2011 |
| 8062638 | Prevention and treatment of diseases associated with blood coagulation Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently sup... | 11/22/2011 |
| 8062639 | Antibodies to bufalin prevent inhibition of Na/K ATPase and prolong survival in shock The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or poly... | 11/22/2011 |
| 8038997 | Anti-marinobufagenin antibodies and methods for their use Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also en... | 10/18/2011 |
| 8034346 | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The inventio... | 10/11/2011 |
| 8034345 | Anti-PCI antibody for regulating liver regeneration/repair The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to... | 10/11/2011 |
| 8025882 | Interferon alpha antibodies and their uses The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity o... | 09/27/2011 |
| 8025881 | BMP antibodies and methods of treating kidney disease using the same When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling p... | 09/27/2011 |
| 8017122 | Methods of using IL-31 monoclonal antibodies to reduce inflammation The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphig... | 09/13/2011 |
| 8017121 | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor. The pharmaceutical composition for treatment of chronic rheumatoid arthritis or syno... | 09/13/2011 |
| 8012482 | Humanized anti-TGF-beta antibodies Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized ... | 09/06/2011 |
| 8007799 | Vascular endothelial cell growth factor antagonists and uses thereof The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and s... | 08/30/2011 |
| 8007800 | Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) a... | 08/30/2011 |
| 8007798 | Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) an... | 08/30/2011 |
| 8003104 | Method for treating inflammation A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such ... | 08/23/2011 |
| 7993645 | Human anti-IL-23 antibodies, compositions, methods and uses A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. ... | 08/09/2011 |
| 7988969 | Treatment for central nervous system disorders Compositions that include an Aβ polypeptide linked to a non-Aβ polypeptide are described, as well as methods of using such compositions. ... | 08/02/2011 |
| 7988968 | Method of treating an IL-1 related coronary condition An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an... | 08/02/2011 |
| 7988967 | High affinity human antibodies to human nerve growth factor A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affini... | 08/02/2011 |
| 7988970 | Methods of treatment comprising administering an anti-sclerostin antibody Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bon... | 08/02/2011 |
